Two-Dose Novavax Vaccine Protects Against SARS-CoV-2 Infection
Vaccine efficacy in adults was 89.7 percent overall, 86.3 percent against B.1.1.7 (alpha) variant, and 96.4 percent against non-B.1.1.7 variants
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.